A detailed history of Bellevue Group Ag transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 809,095 shares of ALNY stock, worth $199 Million. This represents 3.75% of its overall portfolio holdings.

Number of Shares
809,095
Previous 919,834 12.04%
Holding current value
$199 Million
Previous $224 Million 0.43%
% of portfolio
3.75%
Previous 3.74%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$233.81 - $287.01 $25.9 Million - $31.8 Million
-110,739 Reduced 12.04%
809,095 $223 Million
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $222,130 - $382,850
1,550 Added 0.17%
919,834 $224 Million
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $4.83 Million - $6.53 Million
32,966 Added 3.72%
918,284 $137 Million
Q4 2023

Feb 14, 2024

SELL
$151.41 - $196.57 $1.37 Million - $1.77 Million
-9,027 Reduced 1.01%
885,318 $169 Million
Q3 2023

Nov 14, 2023

SELL
$170.77 - $211.65 $905,934 - $1.12 Million
-5,305 Reduced 0.59%
894,345 $158 Million
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $3.03 Million - $3.48 Million
16,400 Added 1.86%
899,650 $171 Million
Q1 2023

May 15, 2023

SELL
$182.66 - $235.53 $6.93 Million - $8.94 Million
-37,963 Reduced 4.12%
883,250 $177 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $6.6 Million - $8.58 Million
-35,549 Reduced 3.72%
921,213 $219 Million
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $14.1 Million - $23.5 Million
-101,424 Reduced 9.58%
956,762 $192 Million
Q2 2022

Aug 11, 2022

SELL
$120.42 - $169.29 $20.6 Million - $29 Million
-171,377 Reduced 13.94%
1,058,186 $154 Million
Q1 2022

May 13, 2022

SELL
$127.18 - $173.91 $13.4 Million - $18.4 Million
-105,577 Reduced 7.91%
1,229,563 $201 Million
Q4 2021

Feb 10, 2022

SELL
$159.56 - $209.29 $11.7 Million - $15.3 Million
-73,278 Reduced 5.2%
1,335,140 $226 Million
Q3 2021

Nov 12, 2021

SELL
$169.75 - $207.73 $23.9 Million - $29.2 Million
-140,674 Reduced 9.08%
1,408,418 $266 Million
Q2 2021

Aug 12, 2021

SELL
$128.63 - $176.89 $10 Million - $13.8 Million
-78,022 Reduced 4.8%
1,549,092 $263 Million
Q1 2021

May 12, 2021

BUY
$126.83 - $175.69 $2.99 Million - $4.15 Million
23,614 Added 1.47%
1,627,114 $230 Million
Q4 2020

Feb 16, 2021

BUY
$122.97 - $147.0 $5.37 Million - $6.42 Million
43,695 Added 2.8%
1,603,500 $208 Million
Q3 2020

Nov 16, 2020

SELL
$121.19 - $165.49 $6.09 Million - $8.32 Million
-50,260 Reduced 3.12%
1,559,805 $227 Million
Q2 2020

Aug 13, 2020

SELL
$104.21 - $156.44 $17.2 Million - $25.8 Million
-165,199 Reduced 9.31%
1,610,065 $238 Million
Q1 2020

May 14, 2020

SELL
$93.12 - $133.99 $8.34 Million - $12 Million
-89,519 Reduced 4.8%
1,775,264 $193 Million
Q4 2019

Feb 14, 2020

SELL
$74.51 - $124.23 $7.47 Million - $12.5 Million
-100,289 Reduced 5.1%
1,864,783 $215 Million
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $2.67 Million - $3.31 Million
37,678 Added 1.95%
1,965,072 $158 Million
Q2 2019

Aug 14, 2019

BUY
$65.86 - $92.79 $109 Million - $154 Million
1,660,089 Added 621.05%
1,927,394 $140 Million
Q1 2019

May 15, 2019

BUY
$72.76 - $93.45 $3.12 Million - $4.01 Million
42,920 Added 19.13%
267,305 $25 Million
Q4 2018

Feb 12, 2019

BUY
$62.67 - $88.33 $281,638 - $396,955
4,494 Added 2.04%
224,385 $16.4 Million
Q3 2018

Nov 13, 2018

BUY
$87.52 - $122.67 $10.2 Million - $14.3 Million
116,391 Added 112.46%
219,891 $19.2 Million
Q2 2018

Aug 07, 2018

BUY
$88.31 - $107.8 $7.22 Million - $8.81 Million
81,750 Added 375.86%
103,500 $10.2 Million
Q1 2018

May 09, 2018

SELL
$115.92 - $148.54 $40,572 - $51,989
-350 Reduced 1.58%
21,750 $2.59 Million
Q4 2017

Feb 14, 2018

SELL
$114.49 - $139.98 $6.12 Million - $7.49 Million
-53,493 Reduced 70.76%
22,100 $2.81 Million
Q3 2017

Nov 13, 2017

SELL
$72.53 - $118.27 $3.59 Million - $5.85 Million
-49,436 Reduced 39.54%
75,593 $8.88 Million
Q2 2017

Aug 14, 2017

BUY
N/A
125,029
125,029 $9.97 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.